Do statins prevent Alzheimer's disease? A narrative review

European Journal of Internal Medicine

Volumn 26, Issue 9, 2015, Pages 666-669

  Daneschvar, Homayoun L ^a   Aronson, Mark D ^a   Smetana, Gerald W ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Dementia; Disease prevention; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DISEASE COURSE; DRUG EFFECT; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PLEIOTROPY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); AGED; BLOOD; PATHOPHYSIOLOGY;

AGED; ALZHEIMER DISEASE; CHOLESTEROL; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84947866440     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.08.012     Document Type: Review

References (45)

1. J.C. de la Torre Alzheimer disease as a vascular disorder: nosological evidence Stroke 33 4 2002 1152 1162
2. P.B. Gorelick, and M. William Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors Stroke 36 4 2005 875 879
3. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs 7/3/2012
4. J.W. Jukema, C.P. Cannon, A.J. de Craen, R.G. Westendorp, and S. Trompet The controversies of statin therapy: weighing the evidence J Am Coll Cardiol 60 10 2012 875 881
5. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 25 2002 3143 3421
6. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 18 1998 1837 1847
7. J. Stamler, D. Wentworth, and J.D. Neaton Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256 20 1986 2823 2828
8. C.G. Mihos, M.J. Salas, and O. Santana The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review Cardiol Rev 18 6 2010 298 304
9. M.S. Brown, and J.L. Goldstein A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood Proc Natl Acad Sci U S A 96 20 1999 11041 11048
10. M.A. Bayorh, A.A. Ganafa, D. Eatman, M. Walton, and G.Z. Feuerstein Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension Am J Hypertens 18 11 2005 1496 1502
11. J.K. Park, D.N. Muller, E.M. Mervaala, R. Dechend, A. Fiebeler, F. Schmidt, and et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects Kidney Int 58 4 2000 1420 1430
12. S. Moncada, and E.A. Higgs Nitric oxide and the vascular endothelium Handbook of experimental pharmacology 176 Pt 1 2006 213 254
13. G. Cirino, S. Fiorucci, and W.C. Sessa Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci 24 2 2003 91 95
14. R.S. Rosenson, C.C. Tangney, and L.C. Casey Inhibition of proinflammatory cytokine production by pravastatin Lancet 353 9157 1999 983 984
15. K. Pahan, F.G. Sheikh, A.M. Namboodiri, and I. Singh Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages J Clin Invest 100 11 1997 2671 2679
16. T.T. Tuomisto, H. Lumivuori, E. Kansanen, S.K. Hakkinen, M.P. Turunen, J.V. van Thienen, and et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2 Cardiovasc Res 78 1 2008 175 184
17. P. Pignatelli, V. Sanguigni, L. Lenti, L. Loffredo, R. Carnevale, R. Sorge, and et al. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin J Thromb Haemost 5 6 2007 1170 1178
18. P.A. McCullough, M.A. Silver, E.D. Kennard, S.F. Kelsey, A.D. Michaels, and I. Investigators Impact of body mass index on outcomes of enhanced external counterpulsation therapy Am Heart J 151 1 2006 139
19. S. Colli, S. Eligini, M. Lalli, M. Camera, R. Paoletti, and E. Tremoli Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis Arterioscler Thromb Vasc Biol 17 2 1997 265 272
20. X.K. Tong, C. Lecrux, P. Rosa-Neto, and E. Hamel Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits J Neurosci Off J Soc Neurosci 32 14 2012 4705 4715
21. A.L. Sosa-Ortiz, I. Acosta-Castillo, and M.J. Prince Epidemiology of dementias and Alzheimer's disease Arch Med Res 43 8 2012 600 608
22. M. Prince, R. Bryce, E. Albanese, A. Wimo, W. Ribeiro, and C.P. Ferri The global prevalence of dementia: a systematic review and metaanalysis Alzheimers Dement 9 1 2013 63 75 [e2]
23. E.S. Musiek, and D.M. Holtzman Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement Curr Opin Neurol 25 6 2012 715 720
24. H.J. Markowitsch, and A. Staniloiu Amnesic disorders Lancet 380 9851 2012 1429 1440
25. P. Giannakopoulos, M. Duc, G. Gold, P.R. Hof, J.P. Michel, and C. Bouras Pathologic correlates of apraxia in Alzheimer disease Arch Neurol 55 5 1998 689 695
26. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, and et al. Inflammation and Alzheimer's disease Neurobiol Aging 21 3 2000 383 421
27. J. Miao, F. Xu, J. Davis, I. Otte-Holler, M.M. Verbeek, and W.E. Van Nostrand Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein Am J Pathol 167 2 2005 505 515
28. J. Poirier, J. Davignon, D. Bouthillier, S. Kogan, P. Bertrand, and S. Gauthier Apolipoprotein E polymorphism and Alzheimer's disease Lancet 342 8873 1993 697 699
29. L.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, R. Mayeux, and et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium JAMA 278 16 1997 1349 1356
30. R.H. Myers, E.J. Schaefer, P.W. Wilson, R. D'Agostino, J.M. Ordovas, A. Espino, and et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study Neurology 46 3 1996 673 677
31. F.W. Pfrieger Cholesterol homeostasis and function in neurons of the central nervous system Cell Mol Life Sci 60 6 2003 1158 1171
32. D.M. Lloyd-Jones, P.W. Wilson, M.G. Larson, E. Leip, A. Beiser, R.B. D'Agostino, and et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages Arch Intern Med 163 16 2003 1966 1972
33. L.M. Refolo, B. Malester, J. LaFrancois, T. Bryant-Thomas, R. Wang, G.S. Tint, and et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model Neurobiol Dis 7 4 2000 321 331
34. K. Fassbender, M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, and et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo Proc Natl Acad Sci U S A 98 10 2001 5856 5861
35. L. Puglielli, R.E. Tanzi, and D.M. Kovacs Alzheimer's disease: the cholesterol connection Nat Neurosci 6 4 2003 345 351
36. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 9242 2000 1627 1631
37. C. Cramer, M.N. Haan, S. Galea, K.M. Langa, and J.D. Kalbfleisch Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study Neurology 71 5 2008 344 350
38. D.L. Sparks, R.J. Kryscio, M.N. Sabbagh, D.J. Connor, L.M. Sparks, and C. Liebsack Reduced risk of incident AD with elective statin use in a clinical trial cohort Curr Alzheimer Res 5 4 2008 416 421
39. M.D. Haag, A. Hofman, P.J. Koudstaal, B.H. Stricker, and M.M. Breteler Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study J Neurol Neurosurg Psychiatry 80 1 2009 13 17
40. K.J. Swiger, R.J. Manalac, R.S. Blumenthal, M.J. Blaha, and S.S. Martin Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects Mayo Clin Proc 88 11 2013 1213 1221
41. Z. Arvanitakis, J.A. Schneider, R.S. Wilson, J.L. Bienias, J.F. Kelly, D.A. Evans, and et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology Neurology 70 19 Pt 2 2008 1795 1802
42. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, and et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 9346 2002 1623 1630
43. Heart Protection Study Collaborative G MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 9326 2002 7 22
44. M.J. Prince, A.M. Macdonald, P.C. Sham, M. Richards, S. Quraishi, and I. Horn The development and initial validation of a telephone-administered cognitive test battery (TACT) Int J Methods Psychiatr Res 8 1 1999 49 57
45. B. McGuinness, D. Craig, R. Bullock, and P. Passmore Statins for the prevention of dementia Cochrane Database Syst Rev 2 2009 CD003160